India faces sudden shortage.
|
|
|
|
|
| | As India prepares to begin exporting HCQ again to some countries after a brief ban, pharmacists and patients say it has almost disappeared from the market. Apart from malaria, the drug is also prescribed to patients (mostly women) suffering from auto-immune diseases such as lupus and rheumatoid arthritis.
While state authorities insist there is no domestic shortage, multiple news reports have quoted panicked patients who are unable to access the drug that keeps their pain in control.
Like many other medicines, the ongoing national lockdown has disrupted the supply of HCQ as well. But the bigger reason for the shortage may be the unproven claim—most famously by US President Donald Trump—that the drug could help COVID-19 patients. |
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| New to this email? You can sign up here.
You can also follow HuffPost India on Flipboard.
©2019 HuffPost lndia | Level 3B, DLF Centre, Sansad Marg, Connaught Place, New Delhi - 110001, India You are recieving this email becuase you signed up for updates from HuffPost India.
Feedback | Privacy Policy | Unsubscribe |
|
|
|
|
|
|
0 comments:
Post a Comment